Business Wire

Baxalta Receives FDA Approval for VONVENDI, the First and Only Recombinant Treatment for Adults Affected by Von Willebrand Disease

BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and ...
Yahoo Finance

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand Disease (VWD) and On-Demand and Perioperative ...
WebMD

FDA Expands Approved Use of Vonvendi

Vonvendi is a lab-made version of von Willebrand factor (VWF), a protein your body needs for blood to clot. Affecting more than 3 million people in the U.S, von Willebrand disease (VWD) is a common ...
Nasdaq

FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) approved VONVENDI® [von ...
Yahoo Finance

FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder

The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in Type 3 von ...
Pharmabiz

Takeda’s Vonvendi receives US FDA expanded indication approval to treat adults and children with Von Willebrand disease

Takeda, a company focused on creating better health for people and a brighter future for the world, announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics ...
Monthly Prescribing Reference

Vonvendi Approved for Peri-Operative Management of Bleeding in VWD Patients

Safety and efficacy of Vonvendi with or without recombinant factor VIII (FVIII) treatment in elective surgical procedures in patients aged ≥18 years diagnosed with severe von Willebrand disease, was ...
PharmaTimes

US expands use of Shire’s Vonvendi

US regulators have expended the scope of Shire’s Vonvendi to include perioperative management of bleeding in adults with von Willebrand disease (VWD). US regulators have expended the scope of Shire’s ...
The Globe and Mail

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI ® [von Willebrand factor ...
Mena FN

U.S. FDA Approves Expanded Indication For VONVENDI® [Von Willebrand Factor (Recombinant)] For Adults And Children With V...

(BUSINESS WIRE )--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI ® [von ...